Mahamaya presentation shows 557 approvals, rather than 576
Key highlights
- Mahamaya’s five approved-registration categories total 557, while its pipeline totals 55 registrations.
- Formulation approvals total 300 and export-only formulation approvals total 199.
- Technical import and technical manufacture each account for 19 pipeline registrations.
- Mahamaya targets March 2027 to raise solid capacity from 1,040 MTPA to 2,000 MTPA.
powered by IRIS

Mahamaya Lifesciences reports 557 approved agrochemical registrations, rather than 576, and 55 registrations in its pipeline based on the five-category table in its presentation. The approved base includes 300 formulation registrations and 199 formulations exclusively for export, while technical import and technical manufacture together account for 57 approvals.
Know Mahamaya Lifesciences inside out
Results, valuation, peers and who's buying, in one view.
How many registrations has Mahamaya approved?
Mahamaya has disclosed 557 approved registrations when the five stated categories are added: 24 technical-import approvals, 33 technical-manufacture approvals, 300 formulation approvals, 199 export-only formulation approvals and one formulation-import approval. This total is 19 below the 576 figure in the topic statement, while the presentation’s 55-item pipeline adds up across the listed categories.
Mahamaya’s approved portfolio is concentrated in formulations, which total 499 of the 557 disclosed approvals when general formulations and export-only formulations are combined. The 199 export-only approvals are 101 below the 300 general formulation approvals, but exceed the combined 57 approvals for technical import and technical manufacture, showing that finished-product registrations constitute most of the disclosed base.
What is in Mahamaya’s 55-registration pipeline?
Mahamaya’s 55 pipeline registrations are weighted toward technical products, with 19 technical-import and 19 technical-manufacture registrations, or 38 technical registrations together. The other disclosed pipeline categories are 15 formulations exclusively for export and two formulations, while the presentation gives no pipeline figure for formulation import.
The mix differs from the approved portfolio because technical registrations make up 38 of 55 pipeline registrations but only 57 of 557 approvals. The presentation describes continuous product additions through regulatory and research-and-development capabilities, but does not disclose application dates, named molecules, approval timing or the probability that any individual pipeline registration will be approved.
The 19 technical-manufacture pipeline registrations are relevant to Mahamaya’s stated plan for in-house technical manufacturing at its existing Dahej, Gujarat facility. Management has outlined planned technical capacity of 250 metric tonnes per annum, or MTPA, project investment of about Rs 30 crore through initial public offering proceeds, and target commissioning in 2028. The registration table does not state that these 19 registrations are tied to that project.
Which crop-protection categories make up Mahamaya’s portfolio?
Mahamaya says insecticides account for 49.7% of category-wise registrations, followed by fungicides at 26.4% and herbicides at 19.1%. Plant growth regulators, or PGRs, represent 1.7%, while other categories represent 3%, making insecticides the largest disclosed category in the registration mix.
The portfolio also includes biological and specialty products, namely biostimulants and PGRs, biopesticides, biofertilizers and adjuvants. Conventional offerings cover insecticides, fungicides and herbicides. Mahamaya provides category percentages rather than category counts, so these percentages cannot be used as a separate reconciliation of the 557 approved registrations.
Mahamaya’s technical-sales list includes Acetamiprid Technical with 99% minimum purity, Atrazine Technical and Imidacloprid Technical with 95% minimum purity, and Pretilachlor Technical and Bispyribac Sodium Technical with 98% minimum purity. Its bulk-formulation list includes Acetamiprid 20% SP, Buprofezin 25% SC and Emamectin benzoate 5% SG, covering both active ingredients and finished formulations.
Got a follow-up? Ask IRIS
How do registrations support Mahamaya’s sales channels?
Mahamaya identifies four sales channels: bulk formulation supply, technical sales, domestic branded sales and export sales. The 199 approvals for formulations exclusively for export align with international supply through distribution partners in the Dominican Republic, Turkey, Egypt and the United Arab Emirates, where business is conducted through the UAE subsidiary.
For domestic branded sales, Mahamaya reports a portfolio of more than 45 products and identifies MAYAMECTIN50, VOLENO50, MAYASHIELD SUPER, UCHIT EW 370, MAYAMRIT GR and JINJOTH as leading brands. The presentation records 23 product launches in 2019, three in 2021, two in 2024 and four in 2026, a disclosed total of 32 launches across those four years.
Those 32 launches should not be equated with registrations because the presentation does not provide launches for every intervening year or link each launch to an approval category. The product-offerings page separately lists 16 export formulations, including Sulphur 80% WDG, Pendimethalin 50% EC and Spinosad 45% SC, illustrating the range of formulations supplied outside India.
What manufacturing capacity supports Mahamaya’s formulation portfolio?
Mahamaya commissioned its Dahej formulation manufacturing facility in 2021, with installed capacity of 1,040 MTPA for solid formulations and 13 lakh litres per annum for liquid formulations. Liquid capacity utilisation was 38.6% in financial year 2026, while Mahamaya says solid-formulation utilisation exceeded installed capacity and additional volumes were supported through contract manufacturing.
The Dahej site makes solid formulations including WDG, SG, GR and WP, alongside liquid formulations including EC, SC, OD and SL. The facility supports bulk formulation sales, branded products and exports, while its testing function checks applicable specifications including Bureau of Indian Standards and Food and Agriculture Organization standards.
Mahamaya plans to raise solid-formulation capacity to 2,000 MTPA from 1,040 MTPA and liquid-formulation capacity to 50 lakh litres per annum from 13 lakh litres. Management has stated investment of about Rs 3.75 crore and a March 2027 target for completion, saying the expansion is intended to support formulation volumes, in-house manufacturing and production flexibility.
Conclusion
Mahamaya’s presentation supports 557 approved registrations and 55 pipeline registrations, not the 576 approvals cited in the topic statement. The approved base is dominated by 499 formulation and export-only formulation approvals, whereas 38 of the 55 pipeline registrations are in technical import and technical manufacture.
The next disclosed milestones are the March 2027 formulation-capacity expansion target and 2028 target commissioning of 250 MTPA of technical manufacturing at Dahej. Progress of the 55 pipeline registrations, execution of the Rs 3.75 crore formulation expansion and the Rs 30 crore technical project are the stated developments to watch next.


